What's Happening?
ImmunityBio presented favorable comparative effectiveness data at the 2026 American Urological Association (AUA) Annual Meeting. The data compared nogapendekin alfa inbakicept-pmln (NAI, ANKTIVA®) plus Bacillus Calmette–Guérin (BCG) against other FDA-approved
therapies for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The results showed that NAI+BCG achieved higher complete response rates and reduced cystectomy risk compared to nadofaragene firadenovec-vncg and TAR-200. The findings suggest that NAI+BCG could offer a more effective and durable treatment option for patients, with fewer adverse events compared to TAR-200.
Why It's Important?
The positive results for NAI+BCG highlight its potential as a leading treatment for BCG-unresponsive NMIBC, a condition with limited effective therapies. The ability to achieve higher complete response rates and reduce the need for cystectomy is significant for patient outcomes, offering a bladder-sparing option. This development could influence treatment guidelines and patient management strategies, providing a new standard of care for this challenging cancer type. The data also supports ImmunityBio's strategy to expand its immunotherapy offerings and address unmet needs in oncology.
What's Next?
ImmunityBio will likely continue to advance NAI+BCG through further clinical trials to confirm these findings and seek regulatory approval for broader use. The company may also explore additional indications for ANKTIVA® and expand its pipeline of immunotherapies. The ongoing development of recombinant BCG and efforts to address the U.S. TICE BCG shortage will be critical in ensuring access to these therapies. The results from AUA 2026 could lead to increased interest and investment in ImmunityBio's approach to cancer treatment.
